Citations

Clear

5 citation(s) found for "Li, Chenglong".

Discovery of PRMT5 N-Terminal TIM Barrel Ligands from Machine-Learning-Based Virtual Screening
Shen, Zhihang , Seabra, Gustavo , Brant, Jason O. , Lewis, Ben , Li, Chenglong , Deleyrolle, Loic , Li, Chenglong , Shirlekar, Kalyanee , Deleyrolle, Loic P.

Mayo Clinic

ACS Omega | January 2, 2025 | Volume: 10 | Issue: 1 | Pages: 1156-1163

10.1021/acsomega.4c08661 | PMID 39829491 Get It

Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study
Kimball, Alexa B. , Podda, Maurizio , Alavi, Afsáneh , Miller, Megan , Shen, Yaung‐Kaung , Li, Shu , Xu, Yan , Han, Chenglong , Fakharzadeh, Steven , DePrimo, Samuel E., Chen, Yanqing , Xu, Yan , Chen, Yanqing , Passeron, Thierry , Papp, K A , Alavi, A , Yang, Ya‐Wen , Munoz, Ernesto, Papp, Kim

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 15, 2023 | Volume: 37 | Issue: 10 | Pages: 2098-2108

10.1111/jdv.19252 | PMID 37317022 Get It

AbstractBackgroundHidradenitis suppurativa (HS) is a chronic inflammatory skin condition that causes substantial physical, emotional and psychological burdens. Guselkumab, a monoclonal antibody that binds to the p19 subunit of interleukin‐23, has demonstrated high levels of efficacy in the treatment of inflammatory diseases, including psoriasis and psoriatic arthritis.ObjectiveTo evaluate the effect of guselkumab on the treatment of HS, a phase 2, multicentre, randomized, placebo‐controlled, double‐blind, proof‐of‐concept study was conducted.MethodsPatients ≥18 years of age with moderate‐to‐severe HS for ≥1 year were randomized to (1) guselkumab 200 mg by subcutaneous (SC) injection every 4 weeks (q4w) through Week 36 (guselkumab SC); (2) guselkumab 1200 mg intravenously (IV) q4w for 12 weeks, then switched to guselkumab 200 mg SC q4w from Weeks 12 through 36 (guselkumab IV); or (3) placebo for 12 weeks, with re‐randomization to guselkumab 200 mg SC q4w at Weeks 16 through 36 (placebo → guselkumab 200 mg) or guselkumab 100 mg SC at Weeks 16, 20, 28 and 36 and placebo at Weeks 24 and 32 (placebo → guselkumab 100 mg). End points included HS clinical response (HiSCR) and patient‐reported outcomes.ResultsAlthough guselkumab SC or guselkumab IV resulted in numerically higher HiSCR versus placebo at Week 16 (50.8%, 45.0%, 38.7%, respectively), statistical significance was not achieved. Numerically greater improvements in patient‐reported outcomes were also observed for guselkumab SC and guselkumab IV versus placebo at Week 16. Through Week 40, no clear differences to suggest a dose response were observed for HiSCR and patient‐reported outcomes.ConclusionsDespite modest improvements, the primary end point was not met and the overall findings do not support the efficacy of guselkumab in the treatment of HS. Clinicaltrials.gov: NCT 03628924.
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Roemeling, Christina A. Von , Doonan, Bently P. , Klippel, Kelena , Schultz, Daniel , Hoang-Minh, Lan , Trivedi, Vrunda , Li, Chenglong , Russell, Rylynn A. , Kanumuri, Raju S. , Sharma, Abhisheak , Mitchell, Duane A. , von Roemeling, Christina A , Tun, Han W , Mitchell, Duane A , Doonan, Bently , Tun, Han W.

Mayo Clinic

Clinical Cancer Research | February 7, 2023 | Volume: 29 | Issue: 9 | Pages: 1751-1762

10.1158/1078-0432.ccr-22-1682 | PMID 36749885 Get It

Abstract Purpose: An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This is partly due to restrictions of the blood-brain barrier and their unique microenvironment. These challenges are most evident in cancers such as lymphoma and melanoma, which are typically responsive to treatment in systemic locations but resistant when established in the brain. We propose interleukin-1 receptor-associated kinase-4 (IRAK-4) as a potential target across these diseases and describe the activity and mechanism of oral IRAK-4 inhibitor CA-4948. Experimental Design: Human primary central nervous system lymphoma (PCNSL) and melanoma brain metastases (MBM) samples were analyzed for expression of IRAK-4 and downstream transcription pathways. We next determined the central nervous system (CNS) applicability of CA-4948 in naïve and tumor-bearing mice using models of PCNSL and MBM. The mechanistic effect on tumors and the tumor microenvironment was then analyzed. Results: Human PCNSL and MBM have high expression of IRAK-4, IRAK-1, and nuclear factor kappa B (NF-κB). This increase in inflammation results in reflexive inhibitory signaling. Similar profiles are observed in immunocompetent murine models. Treatment of tumor-bearing animals with CA-4948 results in the downregulation of mitogen-activated protein kinase (MAPK) signaling in addition to decreased NF-κB. These intracellular changes are associated with a survival advantage. Conclusions: IRAK-4 is an attractive target in PCNSL and MBM. The inhibition of IRAK-4 with CA-4948 downregulates the expression of important transcription factors involved in tumor growth and proliferation. CA-4948 is currently being investigated in clinical trials for relapsed and refractory lymphoma and warrants further translation into PCNSL and MBM.
Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation
Owens, Jake L. , Beketova, Elena , Liu, Sheng, Shen, Qi, Pawar, Jogendra Singh , Asberry, Andrew M. , Yang, Jie, Deng, Xuehong, Elzey, Bennett D., Ratliff, Timothy L. , Cheng, Liang , Choo, Richard, Citrin, Deborah E., Polascik, Thomas J., Wang, Bangchen, Huang, Jiaoti, Li, Chenglong, Hu, Chang-Deng, Citrin, Deborah E. , Wang, Bangchen , Shen, Qi , Wan, Jun , Cheng, Liang , Wang, Bangchen , Owens, Jake L. , Beketova, Elena , Liu, Sheng, Shen, Qi, Pawar, Jogendra Singh , Asberry, Andrew M. , Yang, Jie, Deng, Xuehong, Elzey, Bennett D., Ratliff, Timothy L. , Choo, Richard, Polascik, Thomas J., Wang, Bangchen, Huang, Jiaoti, Li, Chenglong, Hu, Chang-Deng

Mayo Clinic

Molecular Cancer Therapeutics | January 13, 2022 | Volume: 21 | Issue: 3 | Pages: 448-459

10.1158/1535-7163.mct-21-0103 | PMID 35027481 Get It

Abstract Prostate cancer remains the second leading cause of cancer death among American men. Radiotherapy is a potentially curative treatment for localized prostate cancer, and failure to control localized disease contributes to the majority of prostate cancer deaths. Neuroendocrine differentiation (NED) in prostate cancer, a process by which prostate adenocarcinoma cells transdifferentiate into neuroendocrine-like (NE-like) cells, is an emerging mechanism of resistance to cancer therapies and contributes to disease progression. NED also occurs in response to treatment to promote the development of treatment-induced neuroendocrine prostate cancer (NEPC), a highly aggressive and terminal stage disease. We previously demonstrated that by mimicking clinical radiotherapy protocol, fractionated ionizing radiation (FIR) induces prostate cancer cells to undergo NED in vitro and in vivo. Here, we performed transcriptomic analysis and confirmed that FIR-induced NE-like cells share some features of clinical NEPC, suggesting that FIR-induced NED represents a clinically relevant model. Furthermore, we demonstrated that protein arginine methyltransferase 5 (PRMT5), a master epigenetic regulator of the DNA damage response and a putative oncogene in prostate cancer, along with its cofactors pICln and MEP50, mediate FIR-induced NED. Knockdown of PRMT5, pICln, or MEP50 during FIR-induced NED and sensitized prostate cancer cells to radiation. Significantly, PRMT5 knockdown in prostate cancer xenograft tumors in mice during FIR prevented NED, enhanced tumor killing, significantly reduced and delayed tumor recurrence, and prolonged overall survival. Collectively, our results demonstrate that PRMT5 promotes FIR-induced NED and suggests that targeting PRMT5 may be a novel and effective radiosensitization approach for prostate cancer radiotherapy.
Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex
Guvenc, Hacer, Pavlyukov, Marat S. , Joshi, Kaushal, Kurt, Habibe , Banasavadi‐Siddegowda, Yeshavanth , Hong, Christopher S. , Kwon, Chang‐Hyuk, Bhasin, Deepak , Chettiar, Somsundaram, Kitange, Gaspar J. , Park, In‐Hee , Li, Chenglong , Shakhparonov, M. I. , Nakano, Ichiro , Mao, Ping , Yamada, Ryosuke , Sarkaria, Jann N. , Kurt, Habibe

Mayo Clinic

Clinical Cancer Research | December 18, 2012 | Volume: 19 | Issue: 3 | Pages: 631-642

10.1158/1078-0432.ccr-12-0647 | PMID 23251006 Get It

Abstract Purpose: Glioblastoma multiforme (GBM) is a devastating disease. Recent studies suggest that the stem cell properties of GBM contribute to the development of therapy resistance. Experimental Design: The expression of Survivin and Ran was evaluated by immunohistochemistry with GBM tissues, and quantitative reverse transcriptase (qRT)-PCR and immunocytochemistry with patient-derived GBM sphere cultures. With a computational structure-based drug design, 11 small-molecule compounds were designed, synthesized, and evaluated as inhibitor candidates for the molecular interaction of Survivin protein. The molecular mechanism of the lead compound, LLP-3, was determined by Western blot, ELISA, in situ proximity ligation assay, and immunocytochemistry. The effects of LLP-3 treatment on GSCs were evaluated both in vitro and in vivo. Quantitative immunohistochemistry was carried out to compare Survivin expression in tissues from 44 newly diagnosed and 31 recurrent post-chemoradiation GBM patients. Lastly, the sensitivities of temozolomide-resistant GBM spheres to LLP-3 were evaluated in vitro. Results: Survivin and Ran were strongly expressed in GBM tissues, particularly in the perivasculature, and also in patient-derived GSC cultures. LLP-3 treatment disrupted the Survivin–Ran protein complex in cancer cells and abolished the growth of patient-derived GBM spheres in vitro and in vivo. This inhibition was dependent on caspase activity and associated with p53 status of cells. Immunohistochemistry showed that Survivin expression is significantly increased in recurrent GBM compared with newly diagnosed tumors, and temozolomide-resistant GBM spheres exhibited high sensitivities to LLP-3 treatment. Conclusions: Disruption of the Survivin–Ran complex by LLP-3 abolishes survival and growth of GSCs both in vitro and in vivo, indicating an attractive novel therapeutic approach for GBM. Clin Cancer Res; 19(3); 631–42. ©2012 AACR.